Novartis loses Indian Glivec case
This article was originally published in Scrip
Executive Summary
India's Supreme Court has dismissed Novartis' plea in the crucial case concerning its anticancer Glivec (imatinib mesylate) and the interpretation of the controversial Section 3(d) provision of India's patent law.
You may also be interested in...
Novartis’ Entresto Faces Challenge From Natco In India
Natco has launched a cut-price version of sacubitril/valsartan (Novartis' Entresto) on the Indian market and is also believed to have opposed the patent for the heart failure therapy.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.
Asia Deal Watch: Nippon Shinyaku Takes On Intractable Rare Disease With MiNA
Plus deals involving Incyte/CMS, Biocytogen/ABL, Bharat/Biofabri/Bilthoven, Dr. Reddy’s/Pharmazz, Veeda/Heads, Sosei Heptares/GSK, BioGeometry/Sanyou, Ono/Sibylla and Teijin/BioProjet